JPRN-UMIN000043767
Not yet recruiting
未知
agoya University Esophageal Cancer CRT+/-PDT Prognostic Study - NEC2P2 Study
agoya University0 sites150 target enrollmentJuly 6, 2021
ConditionsEsophageal Cancer
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Esophageal Cancer
- Sponsor
- agoya University
- Enrollment
- 150
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) Women who are pregnant, may become pregnant (intentionally), or are breastfeeding. Men who wish their partner to become pregnant. 2\) Patients with concomitant psychosis or psychiatric symptoms that would make it difficult to participate in the study. 3\) Patients with active bacterial and fungal infections (fever of 38 degrees or higher, and bacterial infection documented by imaging or bacteriological examination. (Local infections that do not affect the systemic condition are excluded. 4\) Patients with interstitial pneumonia, pulmonary fibrosis, or severe emphysema. 5\) History of myocardial infarction or unstable angina within 6 months of enrollment. 6\) Patients with poorly controlled valvular disease, dilated cardiomyopathy, or hypertrophic cardiomyopathy. 7\) Other patients who are judged by the physician in charge to be unable to tolerate the treatment prescribed in this study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
For advanced or recurrent esophageal cancer Of combination therapy - docetaxel-cisplatin-5 fluorouracil phase I/II trialAdvanced or recurrent esophageal cancerJPRN-UMIN000014625gifu University30
Completed
Not Applicable
Study of treatment for esophageal cancerEsophageal cancerJPRN-UMIN000040909Graduate School of Medical Sciences,Kyushu University26
Active, not recruiting
Phase 1
Phase II trial in inoperable œsophageal cancer evaluating the feasibility of the combination of definitive chemoradiation with the immune checkpoint blockers Nivolumab +/- Ipilimumab (CRUCIAL)oesophageal squamous cell carcinoma and oeasophageal adenocarcinomaMedDRA version: 20.0Level: PTClassification code 10061534Term: Oesophageal squamous cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10030137Term: Oesophageal adenocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2018-000053-53-ESEuropean Organisation for Research and Treatment of Cancer130
Active, not recruiting
Phase 1
Phase II trial in inoperable œsophageal cancer evaluating the feasibility of the combination of definitive chemoradiation with the immune checkpoint blockers Nivolumab +/- Ipilimumab (CRUCIAL)EUCTR2018-000053-53-DEEuropean Organisation for Research and Treatment of Cancer130
Completed
Not Applicable
Patients’ preferences for esophageal cancer screening strategiesNL-OMON25816Radboud university medical center400